Pharmaceutical carriers containing miRNAs for use in the treatment of fibrotic diseases caused by hyperglycemia
AssigneeUnicyte Ev AG
InventorsMaria Felice Brizzi, Giovanni Camussi
Life of this patent
Estimating the term…
Abstract
The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.
Claims16
A method for treatment of a fibrotic disease caused by hyperglycaemia found in diabetic patients comprising administering to a patient in need thereof a pharmaceutically acceptable carrier carrying microRNA miR222.
A method for treatment of a fibrotic disease caused by hyperglycaemia found in diabetic patients comprising administering to a patient in need thereof at least one extracellular vesicle (EV) engineered to contain miR222 or miR100 in an amount between 1×103 and ×105 molecules/EV higher than the amount present in the naturally-occurring extracellular vesicle (EV), wherein the at least one EV is obtainable by loading miR222 or miR100 ex vivo to an extracellular vesicle isolated from a stem cell or body.
Dependencies are inferred from the claim text.